Renate Strehlau1, Megan Burke1, Tamryn van Aswegen1, Louise Kuhn2,3, Joanne Potterton4. 1. Empilweni Services and Research Unit, Rahima Moosa Mother and Child Hospital, Department of Paediatrics and Child Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 2. Gertrude H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York City, New York, USA. 3. Department of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York City, New York, USA. 4. School of Therapeutic Sciences, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Abstract
BACKGROUND: Neurodevelopmental stimulation programmes can improve developmental outcomes. Antiretroviral therapy (ART) started soon after birth potentially limits the invasion of HIV into the central nervous system. A combination of developmental stimulation and early ART initiation may reduce developmental delays in children with perinatally acquired HIV infection. METHODS: At a single site in Johannesburg, South Africa, we enrolled 36 HIV-infected neonates on ART into an intervention group (IG) participating in a yearlong home-based, neurodevelopmental stimulation programme. Bayley Scales of Infant and Toddler Development-3rd Edition (BSID-III) assessments were conducted at 12 months. Scores were compared with 24 early treated HIV-infected infants in an observational group (OG). BSID-III assessments were also conducted for older children in an OG at 24 or 36 months. Cognitive, language and motor scaled and composite scores were analysed. RESULTS: BSID-III scaled and composite scores were all higher in the IG apart from the gross motor scaled score (9.25 vs. 10, p = 0.1954). Receptive communication scaled score was significantly higher in the IG (10.96 vs. 9, p = 0.0331). IG composite scores were all higher than OG scores. OG children assessed at 24 or 36 months had lower composite scores in all subscales than 12-month OG scores. CONCLUSIONS: Early treated HIV-infected children participating in a neurodevelopmental stimulation programme achieved higher BSID-III scores at 12 months compared with early treated HIV-infected children who did not receive the programme.
BACKGROUND: Neurodevelopmental stimulation programmes can improve developmental outcomes. Antiretroviral therapy (ART) started soon after birth potentially limits the invasion of HIV into the central nervous system. A combination of developmental stimulation and early ART initiation may reduce developmental delays in children with perinatally acquired HIV infection. METHODS: At a single site in Johannesburg, South Africa, we enrolled 36 HIV-infected neonates on ART into an intervention group (IG) participating in a yearlong home-based, neurodevelopmental stimulation programme. Bayley Scales of Infant and Toddler Development-3rd Edition (BSID-III) assessments were conducted at 12 months. Scores were compared with 24 early treated HIV-infected infants in an observational group (OG). BSID-III assessments were also conducted for older children in an OG at 24 or 36 months. Cognitive, language and motor scaled and composite scores were analysed. RESULTS: BSID-III scaled and composite scores were all higher in the IG apart from the gross motor scaled score (9.25 vs. 10, p = 0.1954). Receptive communication scaled score was significantly higher in the IG (10.96 vs. 9, p = 0.0331). IG composite scores were all higher than OG scores. OG children assessed at 24 or 36 months had lower composite scores in all subscales than 12-month OG scores. CONCLUSIONS: Early treated HIV-infected children participating in a neurodevelopmental stimulation programme achieved higher BSID-III scores at 12 months compared with early treated HIV-infected children who did not receive the programme.
Authors: L G Epstein; L R Sharer; J M Oleske; E M Connor; J Goudsmit; L Bagdon; M Robert-Guroff; M R Koenigsberger Journal: Pediatrics Date: 1986-10 Impact factor: 7.124
Authors: Patrice L Engle; Maureen M Black; Jere R Behrman; Meena Cabral de Mello; Paul J Gertler; Lydia Kapiriri; Reynaldo Martorell; Mary Eming Young Journal: Lancet Date: 2007-01-20 Impact factor: 79.321
Authors: Beverly Anne Collisson; Susan A Graham; Jonathan L Preston; M Sarah Rose; Sheila McDonald; Suzanne Tough Journal: J Pediatr Date: 2016-03-08 Impact factor: 4.406
Authors: Kunjal Patel; Xue Ming; Paige L Williams; Kevin R Robertson; James M Oleske; George R Seage Journal: AIDS Date: 2009-09-10 Impact factor: 4.177
Authors: Molly L Nozyce; Sophia S Lee; Andrew Wiznia; Sharon Nachman; Lynne M Mofenson; Mary E Smith; Ram Yogev; Kenneth McIntosh; Kenneth Stanley; Stephen Pelton Journal: Pediatrics Date: 2006-03 Impact factor: 7.124